Drug Price Trends for NDC 00074-3109

Average Pharmacy Cost for 00074-3109

Drug Name	NDC	Price/Unit ($)	Unit	Date
GENGRAF 100 MG CAPSULE	00074-3109-32	7.06777	EACH	2025-01-02
GENGRAF 100 MG CAPSULE	00074-3109-32	6.73134	EACH	2024-12-18
GENGRAF 100 MG CAPSULE	00074-3109-32	6.72578	EACH	2024-11-20
GENGRAF 100 MG CAPSULE	00074-3109-32	6.72578	EACH	2024-10-23
GENGRAF 100 MG CAPSULE	00074-3109-32	6.72133	EACH	2024-09-18
GENGRAF 100 MG CAPSULE	00074-3109-32	6.72133	EACH	2024-08-21

Best Wholesale Price for NDC 00074-3109

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for the Drug NDC: 00074-3109

Understanding the National Drug Code (NDC)

To analyze the market and project prices for a specific drug identified by its NDC (00074-3109), it is crucial to understand what an NDC is and its role in the healthcare system.

• NDC Definition: The National Drug Code (NDC) is a unique 11-digit, 3-segment code assigned to each medication listed under Section 510 of the US Federal Food, Drug, and Cosmetic Act. It helps in tracking drugs from the manufacturer to the point of sale, ensuring accurate distribution and supply chain security[1][5].

Identifying the Drug

To proceed with the analysis, we need to identify the drug associated with the NDC 00074-3109.

• Drug Identification: While the specific details of the drug are not provided in the sources, the NDC can be looked up in databases such as the FDA's NDC directory or other pharmaceutical databases to determine the drug's name, generic name, and other relevant details.

Market Trends Affecting Drug Prices

Several trends and factors influence drug prices, including those related to the NDC 00074-3109.

Specialty Pharmaceuticals and Price Inflation

• Price Increase Projections: According to Vizient, Inc., drug price inflation is projected to grow at 3.8% in 2024, driven in part by specialty pharmaceuticals. This trend could impact the pricing of many drugs, including those with specific NDCs[4].

Regulatory and Reimbursement Policies

• Medicaid and Medicare Reimbursement: Drugs are subject to various reimbursement policies under Medicaid and Medicare. For example, the 340B program requires manufacturers to charge a price no greater than the statutory pricing formula (340B ceiling price) when selling to covered entities. This can affect the pricing and availability of drugs[5].
• Cost Ceiling Limits: Programs like Medi-Cal Rx have cost ceiling limits that can impact the reimbursement for drugs. For instance, claims exceeding certain cost ceilings may require prior authorization, which can influence pricing strategies[2].

Technological Advancements

• AI and Gene Editing: The pharmaceutical industry is undergoing significant changes with the integration of AI and gene editing technologies. These advancements can reduce development costs and time, potentially impacting the pricing of new and existing drugs[3].

Price Projections

Given the current trends and factors, here are some key points to consider for price projections:

Inflation and Market Demand

• Projected Increase: With a projected 3.8% increase in drug prices driven by specialty pharmaceuticals, it is likely that the price of the drug associated with NDC 00074-3109 could see a similar or slightly lower increase, depending on its classification and market demand[4].

Regulatory Impact

• 340B Ceiling Price: If the drug is covered under the 340B program, the price would be calculated based on the Average Manufacturer Price (AMP) minus the Unit Rebate Amount (URA). This could cap the price increase to some extent[5].

Technological and Development Costs

• Reduced Development Costs: With AI accelerating drug development and reducing costs, manufacturers might pass these savings on to consumers, potentially stabilizing or reducing the price of the drug[3].

Example Scenario

Assuming the drug associated with NDC 00074-3109 is a specialty pharmaceutical with moderate demand:

• Current Price: Let's assume the current price per unit is $100.
• Projected Increase: With a 3.8% increase, the new price would be approximately $103.80.
• Regulatory Adjustments: If the drug is subject to 340B pricing or other cost ceiling limits, the actual price increase might be lower, potentially around 2-3% depending on the specific regulations and agreements in place.

Key Takeaways

• NDC Importance: The NDC is crucial for tracking and managing drugs, ensuring safety and accurate reimbursement.
• Market Trends: Specialty pharmaceuticals and technological advancements are key drivers of price changes.
• Regulatory Impact: Programs like 340B and cost ceiling limits can significantly affect drug pricing.
• Price Projections: A projected 3.8% increase in drug prices, adjusted for regulatory and technological factors, can help estimate future prices.

FAQs

1. What is the National Drug Code (NDC)?

   • The NDC is a unique 11-digit code assigned to each medication to track it from the manufacturer to the point of sale.

2. How do regulatory policies affect drug prices?

   • Regulatory policies such as the 340B program and cost ceiling limits can cap price increases and affect reimbursement rates.

3. What role does AI play in drug development and pricing?

   • AI accelerates drug development, reduces costs, and can predict drug success rates, potentially leading to more stable or reduced prices.

4. Why are specialty pharmaceuticals driving drug price inflation?

   • Specialty pharmaceuticals, including weight loss drugs and gene therapies, are seeing increased utilization, driving up overall drug costs.

5. How can healthcare providers manage rising drug costs?

   • Providers can manage costs by optimizing supply chains, leveraging cost-saving programs like 340B, and considering less costly therapies when clinically appropriate.